antibody is UCHT1 and wherein the diphtheria toxin moiety is a truncation of native diphtheria toxin at the carboxy terminus.

31. (Twice amended) The fusion immunotoxin according to claim 30, wherein the truncated toxin moiety is DT390.

E1

32. (Twice amended) The fusion immunotoxin according to claim 31, comprising DT390 linked via its carboxy terminus, optionally via a linker, to the single-chain variable region of the anti-CD3 antibody.

33. (Twice amended) The fusion immunotoxin according to claim 32, wherein the single-chain variable region of the anti-CD3 antibody comprises the variable light domain linked via its carboxy terminus to the variable heavy domain, optionally via a linker.

---

38. (Twice amended) A method for inhibiting rejection of transplanted tissue or organs in a subject, comprising administering to the subject an immunotoxin according to claim 30.

E2

39. (Twice amended) A method for treating a subject with an autoimmune disease, comprising administering to the subject an immunotoxin according to claim 30.

40. (Twice amended) A method of treating T cell leukemias or lymphomas in a subject, comprising administering to the subject an immunotoxin according to claim 30.

E2

41. (Twice amended) A method of treating graft-versus-host disease in a subject, comprising administering to the subject an immunotoxin according to claim 30.

42. (Twice amended) A method of treating acquired immunodeficiency syndrome in a subject, comprising administering to the subject an immunotoxin according to claim 30.

REMARKS

Claims 30-33 and 37-42 are pending in the present application and stand rejected under 35 U.S.C. § 103. Claims 30-33 and 38-42 are amended herein. Attached hereto as Appendix A is a marked-up version of the amended claims, showing the amendments made thereto.

Claims 30, 32, 33, and 38-42 have been amended for the purposes of correcting grammar and for clarification. It is believed that no new matter has been added to the claims as the